Eupraxia Pharmaceuticals Announces Proposed Public Offering
Rhea-AI Summary
Eupraxia Pharmaceuticals (NASDAQ:EPRX, TSX:EPRX) filed a preliminary prospectus supplement on Feb 18, 2026 for a proposed public offering of common shares (or pre-funded warrants) and may grant underwriters a 30-day option for up to an additional 15% of the offering.
The company intends to use net proceeds primarily to advance EP-104GI through preclinical work, Phase 2 and Phase 3 preparations, manufacturing, and commercial readiness, plus additional GI indications, R&D, business development, IP expansion and general corporate purposes. Closing is subject to customary conditions and required TSX and Nasdaq approvals.
Positive
- Proceeds earmarked to advance EP-104GI through Phase 2 and Phase 3 preparations
- Plans to fund expanded clinical studies in additional GI indications
- Capital to support manufacturing and commercial readiness for potential product launch
Negative
- Offering size and price not disclosed, creating uncertainty on dilution
- Closing contingent on TSX and Nasdaq listing approvals and customary conditions
Key Figures
Market Reality Check
Peers on Argus
EPRX was down 2.26% while key biotech peers were mostly positive (e.g., TRDA +0.82%, HRTX +2.59%, TLSA +2.21%, SLS +1.95%), pointing to a stock-specific reaction to capital-raising plans rather than a sector-wide move.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Sep 24 | Offering closing | Negative | -1.2% | Closed US$80.5M offering including full underwriter option exercise. |
| Sep 22 | Offering pricing | Positive | +11.6% | Priced US$70M offering at US$5.50 with 30-day underwriter option. |
| Sep 22 | Proposed offering | Positive | +11.6% | Announced proposed share offering with 15% underwriter option and pipeline uses. |
Previous offerings and related financings often saw modest single-day moves, with both positive and slightly negative reactions, suggesting mixed but generally contained responses to equity raises.
Over the last few quarters, Eupraxia has repeatedly accessed equity markets to fund EP-104GI and broader pipeline development. In September 2025, it proposed, priced, and then closed a sizable public offering managed by the same banks named in today’s deal. Those financings targeted clinical advancement, regulatory submissions, and commercial preparation. Today’s proposed offering follows that pattern, again earmarking proceeds for EP-104GI trials, new gastrointestinal indications, and corporate purposes, extending the company’s capital-supported development trajectory.
Historical Comparison
Past offering-related announcements (3 events) showed an average 7.31% one-day move, framing how markets have historically reacted to Eupraxia’s equity raises.
Financing events since September 2025 have consistently directed proceeds toward advancing EP-104GI, regulatory milestones, manufacturing, and broader GI indications, with today’s proposed raise extending that same capital-fueled development strategy.
Market Pulse Summary
This announcement details a proposed public offering of common shares or pre-funded warrants, with a potential 30-day option for underwriters to buy up to 15% more. Proceeds are earmarked for advancing EP-104GI in eosinophilic esophagitis, expanding into additional GI indications, and general corporate uses. Historically, Eupraxia’s financings have supported larger trials and regulatory work, so investors may focus on execution of planned studies and upcoming clinical readouts when assessing this raise.
Key Terms
pre-funded warrants financial
registration statement on form-10 regulatory
multijurisdictional disclosure system regulatory
AI-generated analysis. Not financial advice.
VICTORIA, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the Company has filed a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated February 5, 2024 (the “Base Prospectus”) in connection with a proposed public offering (the “Offering”) of common shares (the “Common Shares”) of the Company (or pre-funded warrants to purchase Common Shares in lieu thereof). The Supplement was also filed with the U.S. Securities Exchange and Commission (the “SEC”), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on February 7, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.
The Company also expects to grant the underwriters a 30-day option to purchase up to an additional
Cantor and LifeSci Capital are acting as joint book-running managers for the Offering. Bloom Burton is also acting as co-manager for the Offering.
The Company intends to use the net proceeds from the Offering primarily for the continued advancement of EP-104GI for Eosinophilic Esophagitis, including the completion of ongoing preclinical studies, and Phase 2 clinical trials, preparations for a Phase 3 clinical trial including the related regulatory submissions, and manufacturing activities, and to undertake the necessary commercial/market development activities to prepare for the eventual product launch. The Company also intends to use a portion of the proceeds to accelerate and expand its plans to pursue clinical studies with EP-104GI in multiple additional gastrointestinal indications, including in esophageal strictures and fibrostenotic Crohn’s disease. A portion of the proceeds will be allocated to research and development of additional pipeline candidates, business development initiatives, and general corporate purposes, which may include but are not limited to employee salaries, working capital, leases for facilities, administrative expenses, and capital expenditures. The Company may also use a portion of the proceeds to expand its intellectual property portfolio and strengthen its corporate infrastructure to support future growth.
The Supplement and accompanying Base Prospectus contain important detailed information about the Offering. The Supplement and accompanying Base Prospectus relating to and describing the terms of the Offering can be found on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Copies of the Supplement and accompanying Base Prospectus relating to and describing the terms of the Offering may also be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, at 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com, from LifeSci Capital LLC at 1700 Broadway, 40th Floor, New York, New York 10019, or by email at compliance@lifescicapital.com or from Bloom Burton Securities Inc. at ecm@bloomburton.com. Prospective investors should read the Supplement and accompanying Base Prospectus and the other documents the Company has filed before making an investment decision.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs.
Notice Regarding Forward-looking Statements and Information
This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the Offering; the anticipated terms of the Offering, the expectation to grant the underwriters a 30-day option to purchase additional shares, the satisfaction of customary closing conditions related to the Offering and the anticipated use of proceeds from the Offering; and the potential for the Company’s technology to impact the drug delivery process. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company’s active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.
For investor and media inquiries, please contact:
James Meikle, Eupraxia Pharmaceuticals Inc.
236.330.7084
jmeikle@eupraxiapharma.com
or
Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856
kgardner@lifesciadvisors.com
SOURCE Eupraxia Pharmaceuticals Inc.
FAQ
What is Eupraxia (EPRX) proposing in the Feb 18, 2026 public offering filing?
How will the proceeds from the EPRX offering be used to advance EP-104GI?
Does the EPRX offering require stock exchange approvals before closing?
Will the EPRX underwriters have an option to buy more shares in the offering?
Where can investors find the prospectus supplement and base prospectus for EPRX?
